A randomized trial of cerclage vs. 17 α-hydroxyprogesterone caproate for treatment of short cervix

Journal of Perinatal Medicine

Volumn 37, Issue 5, 2009, Pages 473-479

  Keeler, Sean M ^a,b   Kiefer, Daniel ^c   Rochon, Meredith ^a   Quinones, Joanne N ^a   Novetsky, Akiva P ^b   Rust, Orion ^a  

^a LEHIGH VALLEY HOSPITAL   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c WINTHROP UNIVERSITY HOSPITAL   (United States)

Author keywords

17 hydroxyprogesterone caproate; Cervical length; Short cervix; Spontaneous preterm birth

Indexed keywords

17 ALPHA HYDROXYPROGESTERONE CAPROATE; PROGESTERONE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GESTATIONAL AGE; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; POST HOC ANALYSIS; PREGNANCY; PREMATURE LABOR; PRIORITY JOURNAL; RISK FACTOR; SCREENING; TRANSVAGINAL ECHOGRAPHY; UTERINE CERVIX CERCLAGE; UTERINE CERVIX DISEASE;

ADULT; CERCLAGE, CERVICAL; CERVICAL LENGTH MEASUREMENT; FEMALE; HUMANS; HYDROXYPROGESTERONES; INFANT, NEWBORN; INJECTIONS, INTRAMUSCULAR; OBSTETRIC LABOR, PREMATURE; PREGNANCY; PREGNANCY OUTCOME; PREGNANCY TRIMESTER, SECOND; RISK FACTORS; UTERINE CERVICAL INCOMPETENCE; YOUNG ADULT;

EID: 70349469673     PISSN: 03005577     EISSN: 16193997     Source Type: Journal    
DOI: 10.1515/JPM.2009.083     Document Type: Article

References (22)

1. American College of Obstetricians and Gynecologists. ACOG practice bulletin: assessment of risk factors for preterm birth. Obstet Gynecol. 2001;98:709-716
2. Andersen HF, Nugent CE, Wanty SD, Hayashi RH. Prediction of risk for preterm delivery by ultrasonographic measurement of cervical length. Am J Obstet Gynecol. 1990; 163:859-867
3. Beato M. Gene regulation by steroid hormones. Cell. 1989; 56:335-344
4. Berghella V, Odibo AO, Tolosa JE. Cerclage for prevention of preterm birth in women with short cervix found on transvaginal ultrasound examination: a randomized trial. Am J Obstet Gynecol. 2004;191:1311-1317
5. DeFranco EA, O'Brien JM, Adair CD, Lewis DF, Hall DR, Fusy S, et al. Vaginal progesterone is associated with a decrease in risk for early preterm birth and improved neonatal outcome in women with a short cervix: a secondary analysis from a randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol. 2007;30:697-705.
6. Fonseca E, Celik E, Parra M, Singh M, Nicolaides K, for the Fetal Medicine Foundation Second Trimester Screening Group. Progesterone and the risk of preterm birth among women with a short cervix. N Engl J Med. 2007; 357:462-469
7. Fonseca EB, Bittar RE, Carvalho MHB, Zugaib M. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebocontrolled double-blind study. Am J Obstet Gynecol. 2003;188:419-424
8. Garfield RE, Kannan MS, Daniel EE. Gap junction formation in myometrium: control by estrogens, progesterone, and prostaglandins. Am J Physiol. 1980;238:C81-C9.
9. Grazzini E, Guillon G, Mouillac B, Zingg HH. Inhibition of oxytocin receptor function by direct binding of progesterone. Nature. 1998:392:509-512
10. Hamilton BE, Martin JA, Ventura SJ. Births: preliminary data for 2006. Natl Vital Stat Rep. 2007;56:1-18.
11. Hassan SS, Romero R, Berry SM, Dang K, Blackwell SC, Treadwell MC, et al. Patients with an ultrasonographic cervical length G15 mm have nearly a 50% risk of early spontaneous preterm delivery. Am J Obstet Gynecol. 2000;182:1458-1467
12. Heath VCF, Southall TR, Souka AP, Novakov A, Nicolaides KH. Cervical length at 23 weeks of gestation: relation to demographic characteristics and previous obstetric history. Ultrasound Obstet Gynecol. 1998;12:304-311
13. Iams JD, Goldenberg RL, Meis PJ, Mercer BM, Moawad A, Das A, et al. The length of the cervix and the risk of spontaneous premature delivery: National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. N Engl J Med. 1996;334:567-572
14. Meis PJ, Klebanoff M, Thom E, Dombrowski MP, Sibai B, Moawad AH, et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med. 2003;348:2379-2385
15. Norwitz ER, Wilson T. Secretory component: a potential regulator of endometrial-decidual prostaglandin production in early human pregnancy. Am J Obstet Gynecol. 2000;183:108-117
16. Owen J, Yost N, Berghella V, Thom E, Swain M, Dildy GA, et al. Mid-trimester endovaginal sonography in women at high-risk for spontaneous preterm birth. J Am Med Assoc. 2001;286:1340-1348
17. Owen J. Vaginal Ultrasound Trial Consortium, UAB Dept Ob/Gyn, Birmingham, Alabama. Multicenter randomized trial of cerclage for preterm birth prevention in high-risk women with shortened mid-trimester cervical length. Am J Obstet Gynceol. 2008;199:S3.
18. Romero R, Espinoza J, Kusanovic J, Gotsch F, Hassan S, Erez O, et al. The preterm parturition syndrome. Br J Obstet Gynaecol. 2006;113(Suppl 3):17-42.
19. Ruddock NK, Shi S-Q, Jain S, Moore G, Hankins GDV, Romero R, et al. Progesterone, but not 17-alpha-hydroxyprogesterone caproate inhibits human myometrial contractions. Am J Obstet Gynecol. 2008;199:391.e1-7
20. Rust OA, Atlas RO, Reed J, van Gaalen J, Balducci J. Revisiting the short cervix detected by transvaginal ultrasound in the second trimester; why cerclage therapy may not help. Am J Obstet Gynecol. 2001;185;1098-1105
21. Rust OA, Atlas RO, Jones KJ, Benham BN, Balducci J. A randomized trial of cerclage versus no cerclage among patients with ultrasonographically detected secondtrimester preterm dilatation of the internal os. Am J Obstet Gynecol. 2000;183:830-835
22. To MS, Alfirevic Z, Heath VCF, Cicero S, Cacho AM, Williamson PR, et al. Cervical cerclage for prevention of preterm delivery in women with short cervix: randomised controlled trial. Lancet. 2004;363:1849-1853 (Pubitemid 38748638)